Open Access
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
J. Maltzman,Marck Pegram,Saeed Sadeghi,Cristina Oliva,M. John Kennedy,Mikhail Lichinitser,Henry L. Gomez Moreno,S. Stein,L. O'Rourke,Stephen S. Johnston,John Pippen,Alexey Manikhas,Michael F. Press,A. Florance,Gilles Romieu,Véronique Diéras,Xavier Pivot +16 more
Reads0
Chats0
TLDR
It is demonstrated that a combined targeted strategy with letrozole and lapatinib significantly enhances PFS and clinical benefit rates in patients with MBC that coexpresses HR and HER2.About:
The article was published on 2009-11-01 and is currently open access. It has received 869 citations till now. The article focuses on the topics: Letrozole & Lapatinib.read more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn,John Crown,István Láng,Katalin Boér,Igor Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Marcus Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,Camilla Fowst,Xin Huang,Sindy T. Kim,Sophia Randolph,Dennis J. Slamon +17 more
TL;DR: Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens as mentioned in this paper.
Journal ArticleDOI
Deconstructing the molecular portraits of breast cancer.
Aleix Prat,Charles M. Perou +1 more
TL;DR: How the combination of standard clinical‐pathological markers with the information provided by these genomic entities might help further understand the biological complexity of this disease, increase the efficacy of current and novel therapies, and ultimately improve outcomes for breast cancer patients is discussed.
Journal ArticleDOI
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar,Benjamin O. Anderson,Jame Abraham,Rebecca Aft,Doreen M. Agnese,Kimberly H. Allison,Sarah L. Blair,Harold J. Burstein,Chau T. Dang,Anthony D. Elias,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Jairam Krishnamurthy,Janice A. Lyons,P. Kelly Marcom,Jennifer M. Matro,Ingrid A. Mayer,Meena S. Moran,Joanne E. Mortimer,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Hope S. Rugo,Amy M. Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,Erica Stringer-Reasor,Melinda L. Telli,John H. Ward,Jessica Young,Jennifer L. Burns,Rashmi Kumar +34 more
TL;DR: The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Journal ArticleDOI
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne,Rachel Schiff +1 more
TL;DR: The need to better identify a priori the patients whose tumors are most likely to benefit from new treatment combinations targeting both ER and growth factor receptor signaling to block the crosstalk between these pathways and eliminate escape routes is highlighted.
References
More filters
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Journal ArticleDOI
New guidelines to evaluate the response to treatment in solid tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: In this article, the authors proposed a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment.
Journal ArticleDOI
EGFR and cancer prognosis
TL;DR: The EGFR was found to act as a strong prognostic indicator in head and neck, ovarian, cervical, bladder and oesophageal cancers, and in non-small cell lung cancer (NSCLC), EGFR expression only rarely was related to patient outlook.
Journal ArticleDOI
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
M Marty,Francesco Cognetti,Dominique Maraninchi,Raymond Snyder,Louis Mauriac,Michèle Tubiana-Hulin,Stephen Chan,David Grimes,Antonio Antón,Anna Lluch,John Kennedy,Kenneth J. O'Byrne,Pierfranco Conte,Michael D. Green,Carol Ward,Karen Mayne,Jean-Marc Extra +16 more
TL;DR: Tastuzumab combined with docetaxel is superior to docetAXel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.